Inclusion and Exclusion Criteria
| Inclusion criteria | Exclusion criteria |
|---|---|
| Histologically proven malignant insulinoma and inadequately increased insulin/C-peptide levels | Eastern Cooperative Oncology Group performance status > 3 |
| Somatostatin receptor positivity in somatostatin receptor imaging prior therapy (Krenning score 3 or 4) | Pregnancy and breast feeding |
| Proven metastatic disease by imaging or biopsy | No observation period |
| Blood count | No available clinical data in observation period |
| Leukocytes ≥ 1,500/μL | |
| Hemoglobin ≥ 8 g/dL | |
| Platelets ≥ 70,000/μL | |
| Estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2 | |
| Received at least 2 treatment cycles of [90Y]Y-DOTATOC or [177Lu]Lu-DOTATOC therapy | |
| Episodes of hypoglycemia in anamnesis |